Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

" National, Phase III, Radomized, Double-Blind, Double -Dummy, Controlled, Parallel to Evaluate Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) Soft Gel Capsules in the Control of Acute Vertigo Symphtoms From Peripheral Origin"

NCT02112578 is registered in ClinicalTrials.gov with Apsen Farmaceutica S.A. as lead sponsor.

NCT NCT02112578
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02112578 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
" National, Phase III, Radomized, Double-Blind, Double -Dummy, Controlled, Parallel to Evaluate Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) Soft Gel Capsules in the Control of Acute Vertigo Symphtoms From Peripheral Origin"
Lead sponsor
Apsen Farmaceutica S.A.
Phase
Phase 3
Overall status
Completed
Start date
November 1, 2016
Completion date
December 1, 2017
Enrollment
292 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

vertigo, peripheral